You just read:

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

News provided by

Sorrento Therapeutics, Inc.

Jan 09, 2017, 09:00 ET